How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

747 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

122. Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value

be effective in reducing TD symptoms; the use of galantamine, eicosapentaenoic acid, and diltiazem was discouraged. Table B1 in the Appendix lists the interventions evaluated in the AAN guidelines. National Institute for Health Research 23 https://www.journalslibrary.nihr.ac.uk/hta/hta21430#/abstract A more recent systematic review sponsored by the U.K. National Institute for Health Research reported similar results. This review found insufficient evidence due to small and low-quality studies, leading

2017 California Technology Assessment Forum

126. Recommendations on screening for cognitive impairment in older adults

important change. The MMSE and the MoCA tools are commonly used by Canadian clinicians in clinical practice. 14 Treatments include medications such as cho- linesterase inhibitors (i.e., donepezil, rivastigmine and galantamine), dietary supplements and vita- mins, and nonpharmacologic interventions such as exercise, and cognitive training and rehabili- tation. 10 Provincial payment for the medications used in primary care practice is often linked to cognitive assessment scores measured by the screening (...) interventions approved for use in Canada (e.g., cholinesterase inhibitors, such as donepezil, rivastigmine and galantamine), dietary supplements or vitamins and nonpharmacologic interventions (e.g., exer- cise, cognitive training and rehabilitation). The task force workgroup decided to treat the key question regarding the accuracy of screening tools (key question 6 in Appendix 2) as a contex- tual question. This was because there were no trials of screening programs and there was evi- dence that treatment

2015 CPG Infobase

127. Clinical practice guidelines for dementia in Australia Full Text available with Trip Pro

that the person with dementia (or their carer[s] or family) make an appointment to see a dentist to conduct an assessment and formulate a long-term treatment plan. Acetylcholinesterase inhibitors and memantine are routinely prescribed for people with mild to moderate Alzheimer disease in order to delay functional decline, and the guidelines support their use. Based on recent evidence, the guidelines also state that any one of the three acetylcholinesterase inhibitors (donepezil, galantamine or rivastigmine (...) Education Services, Department of Health and Ageing Pharmaceutical Policy Branch, Ahmed R. Post market review: Pharmaceutical Benefits Scheme anti-dementia medicines to treat Alzheimer disease. Canberra: Department of Health, 2012. (accessed Jan 2016). Birks J, Craig D. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006; (1): CD004746. Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2013; (5): CD004744. Malouf R

2016 MJA Clinical Guidelines

128. Cochrane team criticises the ECDC experts' draft advice on oseltamivir use

agents”, had been approved for treatment of dementia in the past [8-10]. Between 1998 and 1999, most of them were taken off the market. None of the medicines approved in or before 1998 still hold a clear indication for treatment of dementia today. Currently, only 4 medicines are indicated for treatment of dementia like in other countries; namely donepezil (brand name: Aricept etc.); cholinesterase inhibitors, galantamine Abstract ?Memantine (brand name: Memary), which was launched in 2011, increases

2016 Med Check - The Informed Prescriber

129. Management of Behavioural and Psychological Symptoms of Dementia (BPSD)

of cholinesterase inhibitor therapy for management of BPSD. In this review they 8 analysed 14 clinical trails examining the efficacy of donepezil, rivastigmine and galantamine for management of BPSD. In this review only three studies showed statistically significant and clinically modest benefit. They supported cholinesterase inhibitor therapy for management of BPSD in the absence of effective and safe alternative therapy. A systematic review by Henry and colleagues 99 and a Cochrane review by Seitz et al 100

2016 Australian and New Zealand Society for Geriatric Medicine

131. Dementia

(NICE) guidelines Dementia: supporting people with dementia and their carers in health and social care [ ] and Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset [ ], the NICE Technology Appraisal Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease [ ], the European Federation of Neurological Societies (EFNS-ENS) Guidelines on the diagnosis and management of disorders associated with dementia [ ], and the Guidelines (...) . May 2011 — minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011. April 2011 — minor update. Text added to reflect new recommendations from NICE regarding acetylcholinesterase inhibitors and memantine: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease . Issued in June 2011. July 2010 — minor update. The NICE quality standard relating to dementia have been added

2019 NICE Clinical Knowledge Summaries

133. Drugs to avoid in 2015

of their disproportionate adverse effects and many interactions with other drugs. None of the available drugs has been shown to slow progression toward dependency, yet all carry a risk of life-threatening adverse effects and severe drug inter - actions (Prescrire Int n° 128 and Rev Prescrire n° 363, 364). It is better to focus on reorganising the patient’s daily life, keeping him or her active, and providing support and help for caring relatives. – Donepezil, galantamine and rivastigmine, three cholinesterase

2015 Prescrire

135. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. Full Text available with Trip Pro

patients at 119 sites; study 2: n = 858 at 158 sites; and study 3: n = 734 at 126 sites). The 24-week studies were conducted from October 2013 to January 2017; final follow-up on January 12, 2017.Idalopirdine (10, 30, or 60 mg/d) or placebo added to cholinesterase inhibitor treatment (donepezil in studies 1 and 2; donepezil, rivastigmine, or galantamine in study 3).Primary end point in all 3 studies: change in cognition total score (range, 0-70; a lower score indicates less impairment) from baseline

2018 JAMA Controlled trial quality: predicted high

136. Galantamine Treatment for Nonfluent Aphasia in Stroke Patients

Galantamine Treatment for Nonfluent Aphasia in Stroke Patients Galantamine Treatment for Nonfluent Aphasia in Stroke Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Galantamine Treatment (...) by: University of North Carolina, Chapel Hill Study Details Study Description Go to Brief Summary: Cognitive impairment after stroke is common and has a major effect on morbidity and quality of life. Acetylcholinesterase inhibitors have demonstrated benefit in vascular dementia, but efficacy in treating more circumscribed cognitive deficits following stroke, such as aphasia, has not been systematically investigated. This study evaluated the efficacy of Galantamine (Reminyl) in subjects with chronic, stable

2010 Clinical Trials

137. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01190761 Recruitment Status : Completed

2010 Clinical Trials

138. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01190748 Recruitment Status

2010 Clinical Trials

139. The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2010 Clinical Trials

140. Effects of Galantamine on Cognition

Effects of Galantamine on Cognition Effects of Galantamine on Cognition - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effects of Galantamine on Cognition The safety and scientific validity of this study (...) Description Go to Brief Summary: Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early twenties, with cognitive impairments and negative symptoms frequently emerging much earlier. Such cognitive impairments and negative symptoms but much milder are also observed in high-risk groups (such as relatives of schizophrenia patients), who may or may not develop the full blown psychotic disorder. Our study plans to recruit such non-ill subjects to test the effects of galantamine

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>